-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA: APPROVES NEW STARTING DOSAGE REGIMEN FOR LEQEMBI SUBCUTANEOUS FORMULATION FOR ALZHEIMER’S DISEASE TREATMENT

Reuters·07/13/2026 18:07:27

Please log in to view news